Published in Br J Clin Pharmacol on July 01, 2013
Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J (2013) 1.15
Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet (2014) 1.05
Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol (2013) 0.98
Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation. Dig Dis Sci (2016) 0.89
Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system. Br J Clin Pharmacol (2015) 0.87
Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban. Clin Pharmacokinet (2014) 0.86
Rivaroxaban and hemostasis in emergency care. Emerg Med Int (2014) 0.84
Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications. Drugs (2014) 0.83
New oral anticoagulants and the cancer patient. Oncologist (2013) 0.83
Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism. Thromb J (2014) 0.81
Pharmacology of anticoagulants used in the treatment of venous thromboembolism. J Thromb Thrombolysis (2016) 0.80
Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk. Vasc Health Risk Manag (2014) 0.79
Erratum to: Pharmacology of anticoagulants used in the treatment of venous thromboembolism. J Thromb Thrombolysis (2016) 0.78
Preventive strategies against bleeding due to nonvitamin K antagonist oral anticoagulants. Biomed Res Int (2014) 0.76
Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin. Gastroenterol Res Pract (2016) 0.75
New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplasty. World J Orthop (2014) 0.75
Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy. Ann Pharmacother (2016) 0.75
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Transection of the oesophagus for bleeding oesophageal varices. Br J Surg (1973) 26.26
Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 16.17
Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med (2010) 9.92
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94
Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med (2011) 7.30
Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.12
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet (2009) 6.83
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med (2008) 6.32
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med (2008) 6.00
Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 4.01
Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.36
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther (2005) 2.63
Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects. Eur J Clin Pharmacol (2005) 2.40
Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol (2008) 2.36
Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet (2011) 2.09
Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis. Scand J Gastroenterol (1989) 1.72
Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol (2010) 1.71
Coagulation disorders in liver disease. Semin Liver Dis (2002) 1.66
Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos (2009) 1.53
Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery. Clin Pharmacokinet (2008) 1.39
Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol (2010) 1.34
The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 1.32
Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol (2007) 1.29
In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther (2011) 1.16
Coagulation assays. Circulation (2005) 1.05
In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans. Drug Metab Dispos (2009) 1.04
Albumin synthesis in cirrhotic subjects with ascites studied with carbonate-14C. J Clin Invest (1969) 1.04
Coagulation disorders in patients with cirrhosis and severe sepsis. Liver Int (2003) 1.02
Determination of rivaroxaban--a novel, oral, direct Factor Xa inhibitor--in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 1.01
Limitations of traditional anticoagulants. Pharmacotherapy (2004) 0.88
Expression and function of P-glycoprotein in rats with carbon tetrachloride-induced acute hepatic failure. J Pharm Pharmacol (2001) 0.78
Cimetidine kinetics and dynamics in patients with severe liver disease. Hepatology (1983) 0.77
Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology (2004) 6.14
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther (2005) 2.63
Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects. Eur J Clin Pharmacol (2005) 2.40
Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology (2005) 2.19
Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology (2008) 2.03
Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology (2003) 1.86
Determinants of hyperhomocysteinemia in patients with chronic liver disease and after orthotopic liver transplantation. Am J Clin Nutr (2003) 1.78
Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation (2009) 1.76
Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol (2010) 1.71
Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology (2010) 1.65
Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis (2013) 1.58
Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. J Hepatol (2011) 1.55
DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery. Cell Metab (2013) 1.55
Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin (2008) 1.42
Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol (2013) 1.40
[Erythema gyratum repens: drug reaction following azathioprine administration in a patient with type I autoimmune hepatitis]. Med Klin (Munich) (2002) 1.39
Determination of reference intervals for serum creatinine, creatinine excretion and creatinine clearance with an enzymatic and a modified Jaffé method. Clin Chim Acta (2004) 1.39
Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology (2005) 1.38
Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol (2010) 1.34
Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol (2007) 1.29
Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin. J Clin Pharmacol (2006) 1.21
Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen. Br J Clin Pharmacol (2006) 1.18
Long-term follow-up after successful interferon therapy of acute hepatitis C. Hepatology (2004) 1.12
Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol (2006) 1.10
Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol (2007) 1.06
Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet (2014) 1.05
Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation. Drug Saf (2008) 1.03
The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct Factor Xa inhibitor. J Clin Pharmacol (2013) 1.03
Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061. Antivir Ther (2006) 1.01
Macitentan: entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol (2011) 1.01
The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther (2013) 1.00
Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial. Hepatology (2003) 1.00
Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Br J Clin Pharmacol (2013) 0.98
Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. Vaccine (2009) 0.97
Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clin Pharmacol Ther (2006) 0.96
Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects. Br J Clin Pharmacol (2014) 0.95
Stent placement with the monorail technique for treatment of mesenteric artery stenosis. J Vasc Interv Radiol (2006) 0.94
Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban - an oral, direct factor Xa inhibitor - in elderly Chinese subjects. Thromb Haemost (2009) 0.93
Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology (2009) 0.92
Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation. Drug Metab Pharmacokinet (2012) 0.91
Nitrate and nitrite in the diet: how to assess their benefit and risk for human health. Mol Nutr Food Res (2014) 0.91
The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection. J Gastroenterol (2011) 0.90
Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation. PLoS One (2011) 0.88
Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection. Hepatology (2008) 0.88
Confirmation of model-based dose selection for a Japanese phase III study of rivaroxaban in non-valvular atrial fibrillation patients. Drug Metab Pharmacokinet (2013) 0.87
Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment. Cancer Chemother Pharmacol (2014) 0.87
Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. Br J Clin Pharmacol (2002) 0.86
Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects. Br J Clin Pharmacol (2009) 0.86
Demonstration of the analgesic efficacy and dose-response of acetylsalicylic acid with pseudoephedrine. J Clin Pharmacol (2010) 0.86
Gender-dependent association of CTLA4 polymorphisms with resolution of hepatitis C virus infection. J Hepatol (2006) 0.85
Opinion on the use of plasma processes for treatment of foods. Mol Nutr Food Res (2013) 0.84
Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C? Hepatology (2004) 0.83
Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes. Br J Clin Pharmacol (2012) 0.83
Cost of treating hepatitis C in Germany: a retrospective multicenter analysis. Eur J Gastroenterol Hepatol (2014) 0.82
Proposal for defining the relevance of drug accumulation derived from single dose study data for modified release dosage forms. Biopharm Drug Dispos (2015) 0.82
Effect of co-administration of rivaroxaban and clopidogrel on bleeding time, pharmacodynamics and pharmacokinetics: a phase I study. Pharmaceuticals (Basel) (2012) 0.82
Quantification of vascular endothelial growth factor, interleukin-8, and basic fibroblast growth factor in plasma of cancer patients and healthy volunteers - comparison of ELISA and microsphere-based multiplexed immunoassay. Clin Chem Lab Med (2008) 0.81
Chronic portal vein thrombosis: transcapsular hepatic collateral vessels and communicating ectopic varices. Radiology (2010) 0.81
Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon-nonresponder patients with chronic hepatitis C. J Hepatol (2002) 0.80
Evaluation of angiotensinogen c.1-44G>A and p.M268T variants as risk factors for fibrosis progression in chronic hepatitis C and liver diseases of various etiologies. Genet Test Mol Biomarkers (2009) 0.80
Metabolomic tissue signature in human non-alcoholic fatty liver disease identifies protective candidate metabolites. Liver Int (2014) 0.80
Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infection. J Hepatol (2008) 0.80
Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber. Thromb Res (2013) 0.79
Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial. Eur J Gastroenterol Hepatol (2007) 0.79
Influences of caffeine, acetazolamide and cognitive stimulation on cerebral blood flow velocities. Prog Neuropsychopharmacol Biol Psychiatry (2005) 0.78
The role of carbon in the nitridic high performance ceramics in the system Si-B-N-C. Solid State Nucl Magn Reson (2005) 0.78
Penetration and accumulation of moxifloxacin in uterine tissue. Int J Gynaecol Obstet (2008) 0.78
Pharmacokinetics of teduglutide in subjects with renal impairment. Eur J Clin Pharmacol (2012) 0.78
Impact of impaired renal function on the pharmacokinetics of the antiepileptic drug lacosamide. Clin Pharmacokinet (2013) 0.76
Single-dose pharmacokinetics, safety, and tolerability of albinterferon alfa-2b in subjects with end-stage renal disease on hemodialysis compared to those in matched healthy volunteers. Antimicrob Agents Chemother (2010) 0.75
[Erythema gyratum repens. Drug hypersensitivity after azathioprine in a patient with type 1 autoimmune hepatitis]. Med Klin (Munich) (2002) 0.75
Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy. Ann Hepatol (2013) 0.75
[Main symptom jaundice--differential diagnosis at the bedside]. Med Klin (Munich) (2007) 0.75
Influence of liver cirrhosis on the pharmacokinetics, pharmacodynamics, and safety of tezosentan. J Clin Pharmacol (2009) 0.75
Pharmacokinetic interactions between simvastatin and setipiprant, a CRTH2 antagonist. Eur J Clin Pharmacol (2014) 0.75
Importance of minimal residual viremia for relapse prediction in patients with chronic hepatitis C genotype 1 infection. Clin Infect Dis (2011) 0.75
Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severity. Eur J Gastroenterol Hepatol (2016) 0.75
Pharmacokinetics and safety of nifedipine GITS/candesartan fixed-dose combination in subjects with hepatic impairment . Int J Clin Pharmacol Ther (2016) 0.75
[Current recommendations for the treatment of chronic hepatitis C]. Z Gastroenterol (2014) 0.75